Intravenous Esomeprazole

  title={Intravenous Esomeprazole},
  author={Gillian M. Keating},
  • G. Keating
  • Published 1 June 2011
  • Medicine
  • PharmacoEconomics
Intravenous esomeprazole (Nexium®) is approved in Europe for the prevention of rebleeding following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers.In a pivotal clinical trial, patients with peptic ulcer bleeding and high-risk stigmata who received intravenous esomeprazole for 72 hours following endoscopic haemostatic therapy were significantly less likely than those receiving intravenous placebo to experience recurrent peptic ulcer bleeding at days 3, 7 and 30. In addition… Expand


Safety and tolerability of high-dose intravenous esomeprazole for prevention of peptic ulcer rebleeding
Esomeprazole, given as a continuous high- dose intravenous infusion followed by an oral regimen after successful endoscopic therapy for PUB, was well tolerated, with no apparent safety concerns from either the high-dose intravenous treatment or oral phases. Expand
Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial.
High-dose intravenous esomeprazole given after successful endoscopic therapy to patients with high-risk peptic ulcer bleeding reduced recurrent bleeding at 72 hours and had sustained clinical benefits for up to 30 days. Expand
Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers.
After endoscopic treatment of bleeding peptic ulcers, a high-dose infusion of omeprazole substantially reduces the risk of recurrent bleeding. Expand
Cost Effectiveness of High-Dose Intravenous Esomeprazole for Peptic Ulcer Bleeding
In patients with PUB, high-dose IV esomeprazole after successful endoscopic haemostasis appears to improve outcomes at a modest increase in costs relative to a no-IV esome prazole strategy from the US and Swedish thirdparty payer perspective. Expand
Cost-effectiveness analysis of high-dose omeprazole infusion as adjuvant therapy to endoscopic treatment of bleeding peptic ulcer.
Intravenous administration of high-dose omeprazole appears to be a cost-effective therapy in reducing the recurrence of bleeding and need for surgery in patients with active bleeding ulcer after initial hemostasis is obtained endoscopically. Expand
A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy.
The use of omeprazole is more effective than cimetidine in increasing intragastric pH and reducing rebleeding episodes in patients with bleeding peptic ulcers after successful endoscopic therapy. Expand
Minimizing Recurrent Peptic Ulcer Hemorrhage After Endoscopic Hemostasis: The Cost-Effectiveness of Competing Strategies
Compared with the usual practice of “watchful waiting,” performing selective second look endoscopy in high risk patients may prevent more cases of rebleeding, surgery, or death at a lower overall cost. Expand
Consensus Recommendations for Managing Patients with Nonvariceal Upper Gastrointestinal Bleeding
The current guidelines are a consensus paper with multisociety representation and are directed primarily to the management of nonvariceal bleeding largely due to peptic ulcers. Expand
Costs of treating bleeding and perforated peptic ulcers in The Netherlands.
The direct costs of hospital treatment of bleeding and perforated ulcers in a university hospital, from data in discharge letters and the hospital management information system, are estimated: comorbidity more than doubled the costs of treatment. Expand
Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
There was no evidence of an overall effect of PPI treatment on all-cause mortality, but PPIs significantly reduced mortality in subgroups when studies conducted in Asia were examined in isolation or when the analysis was confined to patients with high-risk endoscopic findings. Expand